These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 28589938)

  • 1. Antisense oligonucleotide-mediated Dnm2 knockdown prevents and reverts myotubular myopathy in mice.
    Tasfaout H; Buono S; Guo S; Kretz C; Messaddeq N; Booten S; Greenlee S; Monia BP; Cowling BS; Laporte J
    Nat Commun; 2017 Jun; 8():15661. PubMed ID: 28589938
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reducing dynamin 2 (DNM2) rescues
    Buono S; Ross JA; Tasfaout H; Levy Y; Kretz C; Tayefeh L; Matson J; Guo S; Kessler P; Monia BP; Bitoun M; Ochala J; Laporte J; Cowling BS
    Proc Natl Acad Sci U S A; 2018 Oct; 115(43):11066-11071. PubMed ID: 30291191
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reducing dynamin 2 expression rescues X-linked centronuclear myopathy.
    Cowling BS; Chevremont T; Prokic I; Kretz C; Ferry A; Coirault C; Koutsopoulos O; Laugel V; Romero NB; Laporte J
    J Clin Invest; 2014 Mar; 124(3):1350-63. PubMed ID: 24569376
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single Intramuscular Injection of AAV-shRNA Reduces DNM2 and Prevents Myotubular Myopathy in Mice.
    Tasfaout H; Lionello VM; Kretz C; Koebel P; Messaddeq N; Bitz D; Laporte J; Cowling BS
    Mol Ther; 2018 Apr; 26(4):1082-1092. PubMed ID: 29506908
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MTM1 overexpression prevents and reverts BIN1-related centronuclear myopathy.
    Giraud Q; Spiegelhalter C; Messaddeq N; Laporte J
    Brain; 2023 Oct; 146(10):4158-4173. PubMed ID: 37490306
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization and genetic diagnosis of centronuclear myopathies in seven Chinese patients.
    Zhao Y; Zhao Z; Shen H; Bing Q; Hu J
    Neurol Sci; 2018 Dec; 39(12):2043-2051. PubMed ID: 30232666
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Different in vivo impacts of dynamin 2 mutations implicated in Charcot-Marie-Tooth neuropathy or centronuclear myopathy.
    Massana Muñoz X; Buono S; Koebel P; Laporte J; Cowling BS
    Hum Mol Genet; 2019 Dec; 28(24):4067-4077. PubMed ID: 31628461
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mice with muscle-specific deletion of Bin1 recapitulate centronuclear myopathy and acute downregulation of dynamin 2 improves their phenotypes.
    Silva-Rojas R; Nattarayan V; Jaque-Fernandez F; Gomez-Oca R; Menuet A; Reiss D; Goret M; Messaddeq N; Lionello VM; Kretz C; Cowling BS; Jacquemond V; Laporte J
    Mol Ther; 2022 Feb; 30(2):868-880. PubMed ID: 34371181
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cellular, biochemical and molecular changes in muscles from patients with X-linked myotubular myopathy due to MTM1 mutations.
    Bachmann C; Jungbluth H; Muntoni F; Manzur AY; Zorzato F; Treves S
    Hum Mol Genet; 2017 Jan; 26(2):320-332. PubMed ID: 28007904
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A centronuclear myopathy-dynamin 2 mutation impairs skeletal muscle structure and function in mice.
    Durieux AC; Vignaud A; Prudhon B; Viou MT; Beuvin M; Vassilopoulos S; Fraysse B; Ferry A; Lainé J; Romero NB; Guicheney P; Bitoun M
    Hum Mol Genet; 2010 Dec; 19(24):4820-36. PubMed ID: 20858595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Defects in amphiphysin 2 (BIN1) and triads in several forms of centronuclear myopathies.
    Toussaint A; Cowling BS; Hnia K; Mohr M; Oldfors A; Schwab Y; Yis U; Maisonobe T; Stojkovic T; Wallgren-Pettersson C; Laugel V; Echaniz-Laguna A; Mandel JL; Nishino I; Laporte J
    Acta Neuropathol; 2011 Feb; 121(2):253-66. PubMed ID: 20927630
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Centronuclear myopathies: a widening concept.
    Romero NB
    Neuromuscul Disord; 2010 Apr; 20(4):223-8. PubMed ID: 20181480
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sporadic centronuclear myopathy with muscle pseudohypertrophy, neutropenia, and necklace fibers due to a DNM2 mutation.
    Liewluck T; Lovell TL; Bite AV; Engel AG
    Neuromuscul Disord; 2010 Dec; 20(12):801-4. PubMed ID: 20817456
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dynamin-2 reduction rescues the skeletal myopathy of a SPEG-deficient mouse model.
    Li Q; Lin J; Widrick JJ; Luo S; Li G; Zhang Y; Laporte J; Perrella MA; Liu X; Agrawal PB
    JCI Insight; 2022 Aug; 7(15):. PubMed ID: 35763354
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multi-omics comparisons of different forms of centronuclear myopathies and the effects of several therapeutic strategies.
    Djeddi S; Reiss D; Menuet A; Freismuth S; de Carvalho Neves J; Djerroud S; Massana-Muñoz X; Sosson AS; Kretz C; Raffelsberger W; Keime C; Dorchies OM; Thompson J; Laporte J
    Mol Ther; 2021 Aug; 29(8):2514-2534. PubMed ID: 33940157
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Muscle-specific function of the centronuclear myopathy and Charcot-Marie-Tooth neuropathy-associated dynamin 2 is required for proper lipid metabolism, mitochondria, muscle fibers, neuromuscular junctions and peripheral nerves.
    Tinelli E; Pereira JA; Suter U
    Hum Mol Genet; 2013 Nov; 22(21):4417-29. PubMed ID: 23813975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nuclear defects in skeletal muscle from a Dynamin 2-linked centronuclear myopathy mouse model.
    Fongy A; Falcone S; Lainé J; Prudhon B; Martins-Bach A; Bitoun M
    Sci Rep; 2019 Feb; 9(1):1580. PubMed ID: 30733559
    [TBL] [Abstract][Full Text] [Related]  

  • 18. "Necklace" fibers, a new histological marker of late-onset MTM1-related centronuclear myopathy.
    Bevilacqua JA; Bitoun M; Biancalana V; Oldfors A; Stoltenburg G; Claeys KG; Lacène E; Brochier G; Manéré L; Laforêt P; Eymard B; Guicheney P; Fardeau M; Romero NB
    Acta Neuropathol; 2009 Mar; 117(3):283-91. PubMed ID: 19084976
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel mutation in the DNM2 gene impairs dynamin 2 localization in skeletal muscle of a patient with late onset centronuclear myopathy.
    Kierdaszuk B; Berdynski M; Karolczak J; Redowicz MJ; Zekanowski C; Kaminska AM
    Neuromuscul Disord; 2013 Mar; 23(3):219-28. PubMed ID: 23374900
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravenous Administration of a MTMR2-Encoding AAV Vector Ameliorates the Phenotype of Myotubular Myopathy in Mice.
    Danièle N; Moal C; Julien L; Marinello M; Jamet T; Martin S; Vignaud A; Lawlor MW; Buj-Bello A
    J Neuropathol Exp Neurol; 2018 Apr; 77(4):282-295. PubMed ID: 29408998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.